ArticleBreast cancer (Dove Medical Press)2026
Association of Pretreatment ANR and IronMLR With Pathological Response Following Neoadjuvant Chemotherapy in Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reliable biomarkers for predicting response to neoadjuvant chemotherapy (NAC) in breast cancer remain limited. This study evaluated the association of pretreatment Albumin-to-Neutrophil Ratio (ANR) and IronMLR with pathological response following NAC. Methods: This retrospective study included 71 patients with breast cancer treated with NAC. Pretreatment inflammatory indices were calculated from routine blood samples obtained before treatment initiation. ANR and IronMLR were compared across pathological response groups. Receiver operating characteristic (ROC) analysis was performed to evaluate predictive performance. Results: The mean age was 53.9±10.6 years, and pathological complete response (pCR) was achieved in 30 patients (42.3%). ANR was not significantly associated with pathological response (p=0.121). In contrast, IronMLR levels differed significantly among complete responders, partial responders, and non-responders (p<0.001). ROC analysis demonstrated favorable discriminatory performance of IronMLR for predicting treatment response, with an area under the curve of 0.909 (95% CI, 0.832-0.986; p<0.001). An IronMLR cut-off value of 175.40 yielded 77.4% sensitivity and 77.8% specificity. Patients with IronMLR ≥175.40 exhibited significantly higher response rates than those with lower values (96.0% vs 66.7%, p=0.001). Conclusion: Pretreatment IronMLR was significantly associated with pathological response following NAC in patients with breast cancer, whereas ANR showed no significant association. Given its simplicity and accessibility, IronMLR may represent a potentially useful biomarker for treatment stratification. Further prospective multicenter studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.